Please assess the completion status of the following clinical trial:

Trial Title: Synera Venipuncture Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with any tumor type where treatment is received through venipuncture or any procedure that is needle based or who require regular pharmacokinetic (PK) study.~* Is 18 years of age or older.~* Patients expected to undergo the first venipuncture procedure within 5 working days of enrollment.~* Male or female patients~* Has signed the most recent Patient Informed Consent Form~* Has signed a Patient Authorization Form (HIPPA)~Exclusion Criteria:~* Patients with sensitivity to lidocaine, tetracaine, or any other component of the product~* Known sensitivity to any components of test materials (sulphites and adhesives)~* Patients with damaged or broken skin at the designated patch site~* Pregnant or breastfeeding women patients~* Use of any immediate-release single-agent opioid product (ie, morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, or tramadol) or combination products containing acetaminophen or ibuprofen with one of these agents within 4 hours of the patient's visit~* Previous irradiation to the site of the patch

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): First application: Synera (lidocaine 70mg/tetracaine 70mg) patch; Second application: Placebo patch
- Arm 2 (Type: EXPERIMENTAL): First application: Placebo patch; Second application: Synera (lidocaine 70mg/tetracaine 70mg) patch

Based on this trial design, predict the completion outcome and termination type (if applicable).